SAN RAMON, Calif., July 10, 2018 /PRNewswire/ -- RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it was selected as a presenting company at the New York Venture Summit, held July 10-11 in New York City.
"I am delighted that RubrYc Therapeutics was chosen to present at the New York Venture Summit and will use this forum to disclose recent results that demonstrate the power of our platform technology to drive and monitor immune responses to desired epitopes," said Dr. Isaac Bright, CEO of RubrYc Therapeutics. "These data further validate the utility of our antibody discovery platform to identify high-value therapeutic candidates in a time efficient manner."
RubrYc Therapeutics is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company collaborates with biotechnology companies in early drug discovery and develops its own pipeline of therapeutic antibodies.
"The data presented at the New York Venture Summit represent the next phase of development of our antibody discovery platform. We are harnessing this capability to advance our internal programs and to the advantage of our partner companies," said Dr. Matthew Greving Ph.D., Co-founder and VP of Technology at RubrYc Therapeutics.
About RubrYc Therapeutics
Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc. The Company has exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidates that are optimized for clinical development.
Contact:
Isaac J. Bright, MD
CEO
RubrYc Therapeutics, Inc.
2420 Camino Ramon
Suite 125
San Ramon, CA 94583
info@rubryc.com
SOURCE RubrYc Therapeutics, Inc.